Can dose-dense chemotherapy improve outcome in patients with better-prognosis small-cell lung cancer?
Katsuyuki Kiura* and Nagahiro Saijo
Correspondence *2-5-1 Shikata-cho, Okayama 700-8558, Japan
Email kkiura@md.okayama-u.ac.jp
This article has no abstract so we have provided the first paragraph of the full text.
Randomized trials using various dose intensities to treat SCLC have shown inconsistent survival results. Nevertheless, when the same drugs were delivered at the same dose per cycle, the same number of cycles, and the same planned cumulative doses using shorter treatment intervals supported by hematopoietic growth factor, a modest survival benefit was demonstrated in four randomized trials.1 Dose intensity was 106–134% in these trials versus 100% for standard treatment, a moderate increase. Superior results using dose-intensified chemotherapy could therefore be anticipated in the treatment of SCLC.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.